Drug Profile


Alternative Names: CGP 48933; Diovan; Diovane; Kalpress; Miten; Nisis; Provas; Tareg; Valpression; Vals; Varexan

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer ESTEVE; JW Pharmaceutical; Novartis; Zeneca Farma
  • Class Antihypertensives; Branched-chain amino acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
  • Discontinued Pulmonary fibrosis; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jan 2017 Novartis completes a phase III trial in Hypertension (In children) in Belgium, Brazil, France, Germany, Guatemala, Hungary, Italy, Lithuania, Poland and Spain (NCT01617681) (EudraCT2011-005991-40)
  • 29 Apr 2016 Biomarkers information updated
  • 01 Sep 2015 Novartis completes a phase III trial in Hypertension (In children) in Colombia, Finland, Germany, Guatemala, South Korea, Philippines, Poland, Romania, Russia and Singapore (NCT01365481)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top